IMU 8.82% 6.2¢ imugene limited

Media Thread, page-13880

  1. 237 Posts.
    lightbulb Created with Sketch. 1105
    Apologies for the highlighted text,

    onCARlytics represents a paradigm shift in solid tumor treatment, it is our jewel in the crown

    It has the potential to target and eradicate solid tumors that otherwise cannot be treated with approved CAR-T therapies alone.

    onCARlytics is safe and has shown promise both in preclinical studies and early clinical trials, offering a novel approach for solid tumor therapy.

    If successful, onCARlytics could open up 90% of the cancer market and allow CD19 therapies to become an option to treat patients with solid tumours (valued at USD$500B).

    More importantly we are only six months away from learning early results from the OASIS combination trial with Amgen's Blincyto ... you just got to love the science and the unbelievable value proposition it represents

    GLTAH - Go Team Imugene
    .
 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
(20min delay)
Last
6.2¢
Change
-0.006(8.82%)
Mkt cap ! $455.6M
Open High Low Value Volume
6.9¢ 7.1¢ 6.2¢ $3.774M 58.30M

Buyers (Bids)

No. Vol. Price($)
23 3402693 6.2¢
 

Sellers (Offers)

Price($) Vol. No.
6.3¢ 610000 3
View Market Depth
Last trade - 16.10pm 03/09/2024 (20 minute delay) ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.